MX2020005562A - Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. - Google Patents
Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1.Info
- Publication number
- MX2020005562A MX2020005562A MX2020005562A MX2020005562A MX2020005562A MX 2020005562 A MX2020005562 A MX 2020005562A MX 2020005562 A MX2020005562 A MX 2020005562A MX 2020005562 A MX2020005562 A MX 2020005562A MX 2020005562 A MX2020005562 A MX 2020005562A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- antibodies
- subject
- detection
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G01N33/57505—
-
- G01N33/5758—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
La presente solicitud se refiere a anticuerpos anti-PD-L1 y su uso para detectar PD-L1 en una muestra de un sujeto. En algunas modalidades, el sujeto ha sido tratado con un anticuerpo anti-PD-L1 terapéutico y un anti-PD-L1 descrito en la presente no compite por la unión a PD-L1 con el anticuerpo anti-PD-L1 terapéutico. En algunas modalidades, el anticuerpo anti-PD-L1 está unido a un resto detectable, tal como un fluoróforo y el anticuerpo anti-PD-L1 se usa para detectar PD-L1 en un sujeto que usa citometría de flujo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593125P | 2017-11-30 | 2017-11-30 | |
| PCT/US2018/062999 WO2019108755A1 (en) | 2017-11-30 | 2018-11-29 | Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005562A true MX2020005562A (es) | 2020-08-20 |
Family
ID=64744946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005562A MX2020005562A (es) | 2017-11-30 | 2018-11-29 | Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11292843B2 (es) |
| EP (1) | EP3717517A1 (es) |
| JP (1) | JP7402158B2 (es) |
| KR (1) | KR102769570B1 (es) |
| CN (1) | CN111918876B (es) |
| AU (1) | AU2018375150A1 (es) |
| CA (1) | CA3082442A1 (es) |
| IL (1) | IL274754A (es) |
| MX (1) | MX2020005562A (es) |
| TW (1) | TW201927820A (es) |
| WO (1) | WO2019108755A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114929734A (zh) * | 2020-01-09 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 新型含有4-1bbl三聚体的抗原结合分子 |
| WO2023143478A1 (en) * | 2022-01-27 | 2023-08-03 | Crown Bioscience Inc. | Novel anti-cd4 and anti-pd-l1 bispecific antibodies |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5342606A (en) | 1984-10-18 | 1994-08-30 | Board Of Regents, The University Of Texas System | Polyazamacrocyclic compounds for complexation of metal ions |
| US5316757A (en) | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5480990A (en) | 1991-12-10 | 1996-01-02 | The Dow Chemical Company | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5739294A (en) | 1991-12-10 | 1998-04-14 | The Dow Chemical Company | Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents |
| US5462725A (en) | 1993-05-06 | 1995-10-31 | The Dow Chemical Company | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5385893A (en) | 1993-05-06 | 1995-01-31 | The Dow Chemical Company | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5834456A (en) | 1996-02-23 | 1998-11-10 | The Dow Chemical Company | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6372907B1 (en) | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
| EP4331604B9 (en) | 2008-12-09 | 2025-07-23 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| EP3280455A1 (en) * | 2015-04-07 | 2018-02-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Non-invasive imaging of tumor pd-l1 expression |
| KR20180127971A (ko) | 2016-03-23 | 2018-11-30 | 맵스페이스 바이오사이언시즈 (쑤저우) 컴퍼니 리미티드 | 신규 항-pd-l1 항체 |
| CN107298713B (zh) * | 2017-08-15 | 2019-12-06 | 联合益康（北京）生物科技有限公司 | 一种抗pd-l1抗体及应用、制备方法、试剂盒和药物 |
-
2018
- 2018-11-29 WO PCT/US2018/062999 patent/WO2019108755A1/en not_active Ceased
- 2018-11-29 CN CN201880076425.7A patent/CN111918876B/zh active Active
- 2018-11-29 AU AU2018375150A patent/AU2018375150A1/en not_active Abandoned
- 2018-11-29 CA CA3082442A patent/CA3082442A1/en active Pending
- 2018-11-29 KR KR1020207017254A patent/KR102769570B1/ko active Active
- 2018-11-29 JP JP2020528372A patent/JP7402158B2/ja active Active
- 2018-11-29 MX MX2020005562A patent/MX2020005562A/es unknown
- 2018-11-29 EP EP18822195.6A patent/EP3717517A1/en active Pending
- 2018-11-30 TW TW107142873A patent/TW201927820A/zh unknown
-
2020
- 2020-05-18 IL IL274754A patent/IL274754A/en unknown
- 2020-05-27 US US16/885,067 patent/US11292843B2/en active Active
-
2022
- 2022-02-16 US US17/673,648 patent/US20230052312A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019108755A1 (en) | 2019-06-06 |
| EP3717517A1 (en) | 2020-10-07 |
| CN111918876A (zh) | 2020-11-10 |
| KR102769570B1 (ko) | 2025-02-19 |
| TW201927820A (zh) | 2019-07-16 |
| JP7402158B2 (ja) | 2023-12-20 |
| US20200291119A1 (en) | 2020-09-17 |
| KR20200090823A (ko) | 2020-07-29 |
| CN111918876B (zh) | 2024-02-02 |
| AU2018375150A1 (en) | 2020-07-09 |
| US20230052312A1 (en) | 2023-02-16 |
| JP2021507685A (ja) | 2021-02-25 |
| US11292843B2 (en) | 2022-04-05 |
| CA3082442A1 (en) | 2019-06-06 |
| IL274754A (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| CL2021000704A1 (es) | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019) | |
| CO2019012210A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| AR120262A2 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso | |
| MX2019006448A (es) | Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet. | |
| ECSP20082648A (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
| CL2020000281A1 (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39 | |
| MX372658B (es) | Anticuerpos anti-cd3 y metodos de uso. | |
| AR114283A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
| AR110645A1 (es) | Anticuerpos anti-hla-g y uso de los mismos | |
| MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| MX2018000621A (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. | |
| MX2024006565A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| CO2019008675A2 (es) | Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet | |
| CR20190408A (es) | Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t antecedentes | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| UY36538A (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola | |
| BR112017011932A8 (pt) | Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso | |
| MX374976B (es) | Anticuerpos y metodos de uso. | |
| MX2017013286A (es) | Neutralizacion del virus chikungunya mediada por anticuerpos. | |
| ECSP21022299A (es) | Anticuerpos de anti-cd33 y métodos para usarlos | |
| EA201992027A1 (ru) | Водный состав антитела против pd-l1 | |
| MX2020005562A (es) | Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. | |
| MX2018003533A (es) | Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso. |